Published in Ann Neurol on February 01, 1997
Guidelines for the diagnosis and management of individuals with neurofibromatosis 1. J Med Genet (2006) 4.23
Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1. Ann Neurol (2014) 3.01
Astrocyte-specific inactivation of the neurofibromatosis 1 gene (NF1) is insufficient for astrocytoma formation. Mol Cell Biol (2002) 2.65
PTEN dosage is essential for neurofibroma development and malignant transformation. Proc Natl Acad Sci U S A (2009) 2.07
Alterations of BRAF and HIPK2 loci predominate in sporadic pilocytic astrocytoma. Neurology (2009) 2.00
Ophthalmological assessment of children with neurofibromatosis type 1. Eur J Pediatr (2013) 1.99
Inactivation of NF1 in CNS causes increased glial progenitor proliferation and optic glioma formation. Development (2005) 1.85
Advances in the treatment of neurofibromatosis-associated tumours. Nat Rev Clin Oncol (2013) 1.26
Defective cAMP generation underlies the sensitivity of CNS neurons to neurofibromatosis-1 heterozygosity. J Neurosci (2010) 1.25
Visual outcome of a cohort of children with neurofibromatosis type 1 and optic pathway glioma followed by a pediatric neuro-oncology program. Neuro Oncol (2007) 1.20
A multi-disciplinary consensus statement concerning surgical approaches to low-grade, high-grade astrocytomas and diffuse intrinsic pontine gliomas in childhood (CPN Paris 2011) using the Delphi method. Neuro Oncol (2013) 1.06
Impact of vision loss among survivors of childhood central nervous system astroglial tumors. Cancer (2016) 1.06
Neurofibromatosis-1 heterozygosity impairs CNS neuronal morphology in a cAMP/PKA/ROCK-dependent manner. Mol Cell Neurosci (2011) 1.02
Somatic neurofibromatosis type 1 (NF1) inactivation characterizes NF1-associated pilocytic astrocytoma. Genome Res (2012) 1.02
Mouse models of neurofibromatosis 1 and 2. Neoplasia (2002) 0.98
Ultrastructural characterization of the optic pathway in a mouse model of neurofibromatosis-1 optic glioma. Neuroscience (2010) 0.96
Pheochromocytoma associated with neurofibromatosis type 1: concepts and current trends. World J Surg Oncol (2010) 0.96
Optic pathway glioma: outcome and prognostic factors in a surgical series. Childs Nerv Syst (2006) 0.96
Neoplasms associated with germline and somatic NF1 gene mutations. Oncologist (2012) 0.95
The Learning Disabilities Network (LeaDNet): using neurofibromatosis type 1 (NF1) as a paradigm for translational research. Am J Med Genet A (2012) 0.91
Interpreting mammalian target of rapamycin and cell growth inhibition in a genetically engineered mouse model of Nf1-deficient astrocytes. Mol Cancer Ther (2011) 0.90
Neurofibromatosis type 1: modeling CNS dysfunction. J Neurosci (2012) 0.89
Region-specific astrogliosis in brains of mice heterozygous for mutations in the neurofibromatosis type 1 (Nf1) tumor suppressor. Brain Res (1999) 0.89
Diffusion-weighted and dynamic contrast-enhanced imaging as markers of clinical behavior in children with optic pathway glioma. Pediatr Radiol (2008) 0.89
Pediatric low-grade gliomas and the need for new options for therapy: Why and how? Cancer Biol Ther (2009) 0.88
Neurofibromatosis type 1 and sporadic optic gliomas. Arch Dis Child (2002) 0.88
Orbitofacial neurofibromatosis: clinical characteristics and treatment outcome. Eye (Lond) (2011) 0.87
NG2-cells are not the cell of origin for murine neurofibromatosis-1 (Nf1) optic glioma. Oncogene (2013) 0.87
Gene expression analysis identifies potential biomarkers of neurofibromatosis type 1 including adrenomedullin. Clin Cancer Res (2010) 0.86
Pediatric low-grade gliomas: how modern biology reshapes the clinical field. Biochim Biophys Acta (2014) 0.86
No correlation between NF1 mutation position and risk of optic pathway glioma in 77 unrelated NF1 patients. Hum Genet (2016) 0.86
Pediatric brain MRI in neurofibromatosis type I. Eur Radiol (2004) 0.85
RASopathies: unraveling mechanisms with animal models. Dis Model Mech (2015) 0.84
An 80-year experience with optic nerve glioma cases at the Armed Forces Institute of Pathology: evolution from museum to molecular evaluation suggests possibe interventions in the cellular senescence and microglial pathways (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc (2014) 0.83
Magnetic resonance diffusion tensor imaging (MRDTI) of the optic nerve and optic radiations at 3T in children with neurofibromatosis type I (NF-1). Pediatr Radiol (2011) 0.82
The impact of coexisting genetic mutations on murine optic glioma biology. Neuro Oncol (2014) 0.81
Diencephalic tumors in children: a 30-year experience of a single institution. Childs Nerv Syst (2011) 0.81
CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice. J Neuroimmunol (2010) 0.81
Pediatric low-grade glioma survivors experience high quality of life. Childs Nerv Syst (2011) 0.81
Spectrum and prevalence of vasculopathy in pediatric neurofibromatosis type 1. J Child Neurol (2012) 0.80
The molecular biology of WHO grade I astrocytomas. Neuro Oncol (2012) 0.79
Soft tissue sarcomas and central nervous system tumors in children with neurofibromatosis type 1. Childs Nerv Syst (2011) 0.79
Optic nerve tortuosity in children with neurofibromatosis type 1. Pediatr Radiol (2013) 0.79
Radiofrequency ablation and excision of multiple cutaneous lesions in neurofibromatosis type 1. Arch Plast Surg (2013) 0.79
Responsiveness of progressive optic pathway tumors to cisplatin-based chemotherapy in children. Childs Nerv Syst (2008) 0.77
Pediatric gliomas as neurodevelopmental disorders. Glia (2015) 0.77
Correlation of optical coherence tomography parameters with clinical and radiological progression in patients with symptomatic optic pathway gliomas. Graefes Arch Clin Exp Ophthalmol (2013) 0.77
Spontaneous complete regression of hypothalamic pilocytic astrocytoma after partial resection in a child, complicated with Stevens-Johnson syndrome: a case report and literature review. Neurosurg Rev (2015) 0.76
High spatial resolution imaging mass spectrometry of human optic nerve lipids and proteins. J Am Soc Mass Spectrom (2015) 0.76
Investigation of retinal nerve fiber layer thickness in patients with neurofibromatosis-1. Jpn J Ophthalmol (2014) 0.76
Emerging genotype-phenotype relationships in patients with large NF1 deletions. Hum Genet (2017) 0.75
A patient with loss of vision in the right eye and neurofibromatosis type 1. CMAJ (2009) 0.75
Isolated lymphoma of the optic nerve, chiasm and tract: A case report. Oncol Lett (2015) 0.75
Increased Tissue Stiffness in Tumors from Mice with Neurofibromatosis-1 Optic Glioma. Biophys J (2017) 0.75
An Update on the Ophthalmologic Features in the Phakomatoses. J Ophthalmol (2016) 0.75
Von recklinghausens disease: a series of four cases with variable expression. J Maxillofac Oral Surg (2013) 0.75
3-D imaging mass spectrometry of protein distributions in mouse Neurofibromatosis 1 (NF1)-associated optic glioma. J Proteomics (2016) 0.75
De novo development of gliomas in a child with neurofibromatosis type 1, fragile X and previously normal brain magnetic resonance imaging. Radiol Case Rep (2016) 0.75
High-Dose Intravenous Vitamin C Treatment of a Child with Neurofibromatosis Type 1 and Optic Pathway Glioma: A Case Report. Am J Case Rep (2016) 0.75
MRI Screening for Optic Gliomas in Neurofibromatosis Type 1. Pediatr Neurol Briefs (2015) 0.75
Brain Tumors in Neurofibromatosis. Curr Treat Options Neurol (2003) 0.75
[Eye involvement in neurofibromatosis]. Ophthalmologe (2016) 0.75
Human stem cell modeling in neurofibromatosis type 1 (NF1). Exp Neurol (2017) 0.75
Visual prognosis of optic glioma. Childs Nerv Syst (2008) 0.75
Malignant glioma: genetics and biology of a grave matter. Genes Dev (2001) 6.78
Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst (1998) 5.30
Human keratinocytes that express hTERT and also bypass a p16(INK4a)-enforced mechanism that limits life span become immortal yet retain normal growth and differentiation characteristics. Mol Cell Biol (2000) 5.28
PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo. Genes Dev (2001) 4.53
Expression profiling of medulloblastoma: PDGFRA and the RAS/MAPK pathway as therapeutic targets for metastatic disease. Nat Genet (2001) 4.48
Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients. Nature (1992) 4.42
CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated. Cancer Res (1996) 4.42
The NF2 tumor suppressor gene product, merlin, mediates contact inhibition of growth through interactions with CD44. Genes Dev (2001) 3.65
Central nervous system atypical teratoid/rhabdoid tumors of infancy and childhood: definition of an entity. J Neurosurg (1996) 3.51
Cerebral blood volume maps of gliomas: comparison with tumor grade and histologic findings. Radiology (1994) 3.19
Mutations in the gene encoding KRIT1, a Krev-1/rap1a binding protein, cause cerebral cavernous malformations (CCM1). Hum Mol Genet (1999) 3.15
Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children's Cancer Group 921 randomized phase III study. J Clin Oncol (1999) 3.08
The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. Mol Cell (1998) 2.77
Current neurosurgical management and the impact of the extent of resection in the treatment of malignant gliomas of childhood: a report of the Children's Cancer Group trial no. CCG-945. J Neurosurg (1998) 2.75
Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. Nat Med (1999) 2.42
Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. Clin Cancer Res (2001) 2.28
Immunohistochemical survey of p16INK4A expression in normal human adult and infant tissues. Lab Invest (1999) 2.27
Survival and prognostic factors following radiation therapy and chemotherapy for ependymomas in children: a report of the Children's Cancer Group. J Neurosurg (1998) 2.22
Shared allelic losses on chromosomes 1p and 19q suggest a common origin of oligodendroglioma and oligoastrocytoma. J Neuropathol Exp Neurol (1995) 2.19
Astrocyte-specific expression of activated p21-ras results in malignant astrocytoma formation in a transgenic mouse model of human gliomas. Cancer Res (2001) 2.13
cDNA cloning of the type 1 neurofibromatosis gene: complete sequence of the NF1 gene product. Genomics (1991) 2.03
PTEN mutations in gliomas and glioneuronal tumors. Oncogene (1998) 2.01
Fusiform dilatations of the carotid artery following radical surgery of childhood craniopharyngiomas. J Neurosurg (1991) 2.01
Alterations of BRAF and HIPK2 loci predominate in sporadic pilocytic astrocytoma. Neurology (2009) 2.00
Molecular genetic evidence for subtypes of oligoastrocytomas. J Neuropathol Exp Neurol (1997) 1.95
Magnetic resonance scans should replace biopsies for the diagnosis of diffuse brain stem gliomas: a report from the Children's Cancer Group. Neurosurgery (1993) 1.92
Plexiform neurofibromas in NF1: toward biologic-based therapy. Neurology (2002) 1.90
High-resolution, dual-platform aCGH analysis reveals frequent HIPK2 amplification and increased expression in pilocytic astrocytomas. Oncogene (2008) 1.84
Long survival and therapeutic responses in patients with histologically disparate high-grade gliomas demonstrating chromosome 1p loss. J Neurosurg (2000) 1.82
Malignant peripheral nerve sheath tumors in neurofibromatosis 1. Am J Med Genet (2000) 1.76
Survival of infants with malignant astrocytomas. A Report from the Childrens Cancer Group. Cancer (1995) 1.67
Subsets of glioblastoma multiforme defined by molecular genetic analysis. Brain Pathol (1993) 1.67
Chronic lymphocytic leukemia and the central nervous system: a clinical and pathological study. Neurology (1996) 1.66
Intramedullary cavernous angiomas of the spinal cord: clinical presentation, pathological features, and surgical management. Neurosurgery (1992) 1.65
Exon scanning for mutation of the NF2 gene in schwannomas. Hum Mol Genet (1994) 1.62
Heterogeneity of clinical severity and molecular lesions in Aicardi syndrome. J Pediatr (1990) 1.62
Familial schwannomatosis: exclusion of the NF2 locus as the germline event. Neurology (2003) 1.57
The photic sneeze reflex: literature review and discussion. Neurology (1993) 1.55
Interdomain binding mediates tumor growth suppression by the NF2 gene product. Oncogene (1997) 1.55
Complement depletion facilitates the infection of multiple brain tumors by an intravascular, replication-conditional herpes simplex virus mutant. J Virol (2000) 1.54
Cancer-related gene expression profiles in NF1-associated pilocytic astrocytomas. Neurology (2001) 1.54
Intracranial ependymomas in children. Int J Radiat Oncol Biol Phys (1990) 1.53
Malignant transformation of neurofibromas in neurofibromatosis 1 is associated with CDKN2A/p16 inactivation. Am J Pathol (1999) 1.52
Pathology with clinical correlations of primary central nervous system non-Hodgkin's lymphoma. The Massachusetts General Hospital experience 1958-1989. Cancer (1994) 1.52
Adult medulloblastoma: prognostic factors and patterns of relapse. Neurosurgery (2000) 1.49
p53 mutations are associated with 17p allelic loss in grade II and grade III astrocytoma. Cancer Res (1992) 1.48
NF1 plexiform neurofibroma growth rate by volumetric MRI: relationship to age and body weight. Neurology (2007) 1.47
NHE-RF, a merlin-interacting protein, is primarily expressed in luminal epithelia, proliferative endometrium, and estrogen receptor-positive breast carcinomas. Am J Pathol (2001) 1.47
Mutations in the neurofibromatosis 1 gene in sporadic malignant melanoma cell lines. Nat Genet (1993) 1.45
Association of loss of heterozygosity on chromosome 17p with high platelet-derived growth factor alpha receptor expression in human malignant gliomas. Cancer Res (1996) 1.44
Low-stage medulloblastoma: final analysis of trial comparing standard-dose with reduced-dose neuraxis irradiation. J Clin Oncol (2000) 1.44
Molecular pathways in the formation of gliomas. Glia (1995) 1.43
Differential effects of cAMP in neurons and astrocytes. Role of B-raf. J Biol Chem (1999) 1.43
A conserved alternative splice in the von Recklinghausen neurofibromatosis (NF1) gene produces two neurofibromin isoforms, both of which have GTPase-activating protein activity. Mol Cell Biol (1993) 1.43
Chromosome abnormalities in pediatric brain tumors. Cancer Res (1988) 1.42
Downregulation of RUNX3 and TES by hypermethylation in glioblastoma. Oncogene (2006) 1.41
Prognostic factors in pediatric brain-stem gliomas. J Neurosurg (1986) 1.40
Survey of somatic mutations in tuberous sclerosis complex (TSC) hamartomas suggests different genetic mechanisms for pathogenesis of TSC lesions. Am J Hum Genet (2001) 1.39
Treatment of diencephalic syndrome with chemotherapy: growth, tumor response, and long term control. Cancer (1998) 1.39
A transcript map of the chromosome 19q-arm glioma tumor suppressor region. Genomics (2000) 1.39
Tumor location and growth pattern correlate with genetic signature in oligodendroglial neoplasms. Cancer Res (2001) 1.38
The retinoblastoma gene is involved in malignant progression of astrocytomas. Ann Neurol (1994) 1.37
Association of EGFR gene amplification and CDKN2 (p16/MTS1) gene deletion in glioblastoma multiforme. Brain Pathol (1997) 1.37
Evidence for a tumor suppressor gene on chromosome 19q associated with human astrocytomas, oligodendrogliomas, and mixed gliomas. Cancer Res (1992) 1.33
Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendrogliomas. Int J Radiat Oncol Biol Phys (2000) 1.32
Analysis of the neurofibromatosis 2 gene reveals molecular variants of meningioma. Am J Pathol (1995) 1.32
EHD2, EHD3, and EHD4 encode novel members of a highly conserved family of EH domain-containing proteins. Genomics (2000) 1.31
Mutational analysis of CDKN2 (MTS1/p16ink4) in human breast carcinomas. Cancer Res (1994) 1.29
Intracranial gliomas in neurofibromatosis type 1. Am J Med Genet (1999) 1.29
Oligodendrocyte lineage genes (OLIG) as molecular markers for human glial brain tumors. Proc Natl Acad Sci U S A (2001) 1.29
Association of epidermal growth factor receptor gene amplification with loss of chromosome 10 in human glioblastoma multiforme. J Neurosurg (1992) 1.28
Mgmt methylation is a prognostic biomarker in elderly patients with newly diagnosed glioblastoma. Neurology (2009) 1.27
Genetic and cellular defects contributing to benign tumor formation in neurofibromatosis type 1. Hum Mol Genet (2000) 1.27
Correlation of high-resolution magic angle spinning proton magnetic resonance spectroscopy with histopathology of intact human brain tumor specimens. Cancer Res (1998) 1.26
Brainstem gliomas in children. A Children's Cancer Group review of 119 cases. Pediatr Neurosurg (1996) 1.25
Molecular genetic correlates of p16, cdk4, and pRb immunohistochemistry in glioblastomas. J Neuropathol Exp Neurol (1998) 1.24
Correlation of neurosurgical subspecialization with outcomes in children with malignant brain tumors. Neurosurgery (2000) 1.24
Mammalian target of rapamycin: master regulator of cell growth in the nervous system. Histol Histopathol (2007) 1.22
CNS germ cell tumor (CNSGCT) of childhood: presentation and delayed diagnosis. Neurology (2007) 1.22
Neoadjuvant chemotherapy for newly diagnosed germ-cell tumors of the central nervous system. J Neurosurg (1987) 1.22
Merlin differentially associates with the microtubule and actin cytoskeleton. J Neurosci Res (1998) 1.21
Aggressive phenotypic and genotypic features in pediatric and NF2-associated meningiomas: a clinicopathologic study of 53 cases. J Neuropathol Exp Neurol (2001) 1.21
Analysis of the neurofibromatosis 2 gene in human ependymomas and astrocytomas. Cancer Res (1994) 1.20
Long-term outcome of hypothalamic/chiasmatic astrocytomas in children treated with conservative surgery. J Neurosurg (1995) 1.19
Cerebral gangliogliomas during childhood. Neurosurgery (1983) 1.19
Monosomy 22 in rhabdoid or atypical tumors of the brain. J Neurosurg (1990) 1.18
Mutational analysis of patients with neurofibromatosis 2. Am J Hum Genet (1994) 1.17
Late-onset optic pathway tumors in children with neurofibromatosis 1. Neurology (2004) 1.17
A rapid and non-radioactive PCR based assay for the detection of allelic loss in human gliomas. Neuropathol Appl Neurobiol (1993) 1.17
Central neurocytomas of the cervical spinal cord. Report of two cases. J Neurosurg (1994) 1.16
NF1 deletions in S-100 protein-positive and negative cells of sporadic and neurofibromatosis 1 (NF1)-associated plexiform neurofibromas and malignant peripheral nerve sheath tumors. Am J Pathol (2001) 1.16
Selective inactivation of p53 facilitates mouse epithelial tumor progression without chromosomal instability. Mol Cell Biol (2001) 1.16
Merlin, DAL-1, and progesterone receptor expression in clinicopathologic subsets of meningioma: a correlative immunohistochemical study of 175 cases. J Neuropathol Exp Neurol (2000) 1.16
Primitive neuroectodermal tumors of the central nervous system. Patterns of expression of neuroendocrine markers, and all classes of intermediate filament proteins. Lab Invest (1990) 1.15
A locus for cerebral cavernous malformations maps to chromosome 7q in two families. Genomics (1995) 1.15
Procarbazine, lomustine, and vincristine (PCV) chemotherapy for grade III and grade IV oligoastrocytomas. J Neurosurg (1996) 1.14
Outcome for children with supratentorial primitive neuroectodermal tumors treated with surgery, radiation, and chemotherapy. Cancer (2000) 1.14
Cervical cord compression from plexiform neurofibromas in neurofibromatosis 1. J Neurol Neurosurg Psychiatry (2007) 1.14
Loss of neurofibromin is associated with activation of RAS/MAPK and PI3-K/AKT signaling in a neurofibromatosis 1 astrocytoma. J Neuropathol Exp Neurol (2000) 1.14
Pilot study of high-dose thiotepa and etoposide with autologous bone marrow rescue in children and young adults with recurrent CNS tumors. The Children's Cancer Group. J Clin Oncol (1996) 1.13